Archived articleThis is an archived article from 2019 - please note that any content within the article may be out of date.
Fda approval coming up
Surely fda approval before Jan?
Disclaimer
This is not financial advice. Our content is intended to be used and must be used for information and education purposes only. Please read our disclaimer and terms and conditions to understand our obligations.
2 comments
I suspect the stock is AIMT, a US Pharma on Nasdaq. It's waiting for FDA approval in January, the product is Palisade, to help people with a peanut allergy.
It's an interesting proposition in that it isn't really a drug as such, it's simply very small doses of peanut which, over time, allows the body to build up its own protection from the allergy, it is not however a cure in that protection remains limited to a couple of peanuts, and not necessarily that amount for all patients. Nothing new there, in that this approach is used for numerous allergies, but the thing that is new, is that if approved by the FDA it can be prescribed, ie I interpret it as a vehicle for prescription rather than a revolutionary "drug". Having said that, that in itself is something I guess.
I've been watching it for a little while but can't quite bring myself to buy. My concerns relate to whether there is actually any protection for the "drug", I simply have no idea, but my assumption is that if there is no protection, it can be readily copied. Also very large short interest. Until I can get a handle on the protection\IP I remain on the sidelines.
For what?